Stem Cell Therapy Market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period, according to a new report by MarketsandMarkets™.
Growth Drivers
Key drivers of the stem cell therapy market include increase in
stem cell research funding, expanding number of clinical trials related to stem
cell therapies, and growing number of GMP-certified cell therapy production
facilities. However, high costs associated with the development of stem cell
therapy along with the ethical concerns related to embryonic stem cells are
likely to hamper the market growth to a certain extent.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48
Browse in-depth TOC on "Stem
Cell Therapy Market"
155 – Tables
43 – Figures
166 – Pages
Market Segmentation
The adipose tissue-derived MSCs segment dominates
the cell source market in the stem cell therapy through 2020-2027.
The global stem cell therapy market is segmented into adipose
tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs,
placenta/umbilical cord-derived MSCs, and other cell sources. Adipose-derived
stem cell tissues can be obtained easily and also possess a variety of the
regenerative properties similar to other mesenchymal stem cells/tissues. These
cells are multipotent and are easy to isolate & harvest; these qualities
have collectively rendered the adipose tissue-derived MSCs segment highest
revenue in 2021.
In 2021, the musculoskeletal disorders ranked first
in terms of revenue in the stem cell therapy market.
Based on therapeutic application, the global stem cell therapy
market is segmented into musculoskeletal disorders, wounds & injuries,
cardiovascular diseases, surgeries, inflammatory & autoimmune diseases,
neurological disorders, and other therapeutic applications. In 2021, the
musculoskeletal disorders application segment accounted for the largest share
of the stem cell therapy market. Increasing market availability of stem
cell-based therapeutic products across major markets and the growing patient
preference for effective & early treatment strategies are driving the
growth of this segment.
Request For 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=48
Regional Analysis
The Asia
Pacific region is the fastest-growing region of the
stem cell therapy market in 2021.
The Asia Pacific region
is estimated to grow at the highest CAGR in the stem cell therapy market during
the forecast period. Japan and South Korea are the key revenue contributors of the Asia Pacific stem cell therapy market. Favorable government
support for product approvals and the presence of major players in these
countries are anticipated to drive the regional market growth.
Top Key Players:
The stem cell therapy market is consolidated in nature with
prominent players in the stem cell therapy market include Smith+Nephew (UK),
MEDIPOST Co., Ltd. (South Korea),
Anterogen Co., Ltd. (South Korea),
CORESTEM (South Korea),
Pharmicell Co., Ltd. (South Korea),
NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals
Co., Ltd. (Japan),
Takeda Pharmaceutical Company Limited (Japan),
Holostem Terapie Avanzate Srl (Italy),
Orthofix (US), Regrow Biosciences Pvt Ltd. (India),
and STEMPEUTICS RESEARCH PVT LTD. (India).
No comments:
Post a Comment